Fatal, ischemic and bleeding risk of patients meeting the selection criteria of the TWILIGHT trial: Insights from a large PCI registry

A Spirito, WJ Koh, S Sartori, B Vogel, Y Feng… - American Heart …, 2023 - Elsevier
Background The TWILIGHT trial (NCT02270242) demonstrated that in selected high-risk
patients undergoing percutaneous coronary intervention (PCI) ticagrelor monotherapy …

[HTML][HTML] β1-blockers in the reduction of bleeding risk in patients prescribed with potent dual antiplatelet therapy after acute coronary syndrome or percutaneous …

S Zhang, Y Wu, C Lv, H Liu, Y Wang, L Dong… - Hellenic Journal of …, 2023 - Elsevier
Background β1-blockers could improve clinical outcomes in patients with coronary artery
disease by lowering the heart rate, blood pressure, and myocardial contractility. Moreover …

Percutaneous Coronary Intervention in Men, Women, and Minorities With a Previous Coronary Artery Bypass Graft Surgery (from the Pooled PLATINUM Diversity and …

FJ Beerkens, D Cao, W Batchelor, S Sartori… - The American Journal of …, 2023 - Elsevier
There is limited data on new-generation stent outcomes in patients with previous coronary
artery bypass graft (CABG) and the associated risk of gender and race/ethnicity is unclear …

[HTML][HTML] Short DAPT for PCI after CABG: ready for prime time

JM Siller-Matula, S Sandner - EuroIntervention, 2022 - ncbi.nlm.nih.gov
A short dual antiplatelet therapy (DAPT) duration with a subsequent switch to single
antiplatelet therapy (SAPT) or de-escalation to a less potent P2Y12 inhibitor has emerged as …

[引用][C] Non-ST-elevation acute coronary syndromes with previous coronary artery bypass grafting: is a routine invasive strategy needed?

FJ Beerkens, DL Bhatt - European Heart Journal, 2024 - academic.oup.com
Non-ST-elevation acute coronary syndromes with previous coronary artery bypass grafting: is
a routine invasive strategy needed? Page 1 Non-ST-elevation acute coronary syndromes with …